BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 10523339)

  • 1. Mutants of 11beta-hydroxysteroid dehydrogenase (11-HSD2) with partial activity: improved correlations between genotype and biochemical phenotype in apparent mineralocorticoid excess.
    Nunez BS; Rogerson FM; Mune T; Igarashi Y; Nakagawa Y; Phillipov G; Moudgil A; Travis LB; Palermo M; Shackleton C; White PC
    Hypertension; 1999 Oct; 34(4 Pt 1):638-42. PubMed ID: 10523339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human hypertension caused by mutations in the 11 beta-hydroxysteroid dehydrogenase gene: a molecular analysis of apparent mineralocorticoid excess.
    Whorwood CB; Stewart PM
    J Hypertens Suppl; 1996 Dec; 14(5):S19-24. PubMed ID: 9120678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apparent mineralocorticoid excess: genotype is correlated with biochemical phenotype.
    Mune T; White PC
    Hypertension; 1996 Jun; 27(6):1193-9. PubMed ID: 8641723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apparent mineralocorticoid excess in a Brazilian kindred: hypertension in the heterozygote state.
    Li A; Li KX; Marui S; Krozowski ZS; Batista MC; Whorwood CB; Arnhold IJ; Shackleton CH; Mendonca BB; Stewart PM
    J Hypertens; 1997 Dec; 15(12 Pt 1):1397-402. PubMed ID: 9431844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular basis for hypertension in the "type II variant" of apparent mineralocorticoid excess.
    Li A; Tedde R; Krozowski ZS; Pala A; Li KX; Shackleton CH; Mantero F; Palermo M; Stewart PM
    Am J Hum Genet; 1998 Aug; 63(2):370-9. PubMed ID: 9683587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A mutation in the cofactor-binding domain of 11beta-hydroxysteroid dehydrogenase type 2 associated with mineralocorticoid hypertension.
    Odermatt A; Dick B; Arnold P; Zaehner T; Plueschke V; Deregibus MN; Repetto H; Frey BM; Frey FJ; Ferrari P
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1247-52. PubMed ID: 11238516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A genetic defect resulting in mild low-renin hypertension.
    Wilson RC; Dave-Sharma S; Wei JQ; Obeyesekere VR; Li K; Ferrari P; Krozowski ZS; Shackleton CH; Bradlow L; Wiens T; New MI
    Proc Natl Acad Sci U S A; 1998 Aug; 95(17):10200-5. PubMed ID: 9707624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Point mutations abolish 11 beta-hydroxysteroid dehydrogenase type II activity in three families with the congenital syndrome of apparent mineralocorticoid excess.
    Ferrari P; Obeyesekere VR; Li K; Wilson RC; New MI; Funder JW; Krozowski ZS
    Mol Cell Endocrinol; 1996 May; 119(1):21-4. PubMed ID: 8793850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular analysis of 11 beta-hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess.
    White PC; Mune T; Rogerson FM; Kayes KM; Agarwal AK
    Steroids; 1997 Jan; 62(1):83-8. PubMed ID: 9029720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Late-onset apparent mineralocorticoid excess caused by novel compound heterozygous mutations in the HSD11B2 gene.
    Lavery GG; Ronconi V; Draper N; Rabbitt EH; Lyons V; Chapman KE; Walker EA; McTernan CL; Giacchetti G; Mantero F; Seckl JR; Edwards CR; Connell JM; Hewison M; Stewart PM
    Hypertension; 2003 Aug; 42(2):123-9. PubMed ID: 12860834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new compound heterozygous mutation in the 11 beta-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess.
    Kitanaka S; Katsumata N; Tanae A; Hibi I; Takeyama K; Fuse H; Kato S; Tanaka T
    J Clin Endocrinol Metab; 1997 Dec; 82(12):4054-8. PubMed ID: 9398712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess.
    Dave-Sharma S; Wilson RC; Harbison MD; Newfield R; Azar MR; Krozowski ZS; Funder JW; Shackleton CH; Bradlow HL; Wei JQ; Hertecant J; Moran A; Neiberger RE; Balfe JW; Fattah A; Daneman D; Akkurt HI; De Santis C; New MI
    J Clin Endocrinol Metab; 1998 Jul; 83(7):2244-54. PubMed ID: 9661590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in the 11 beta-hydroxysteroid dehydrogenase type II enzyme associated with hypertension and possibly stillbirth.
    Krozowski ZS; Stewart PM; Obeyesekere VR; Li K; Ferrari P
    Clin Exp Hypertens; 1997; 19(5-6):519-29. PubMed ID: 9247735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase.
    Mune T; Rogerson FM; Nikkilä H; Agarwal AK; White PC
    Nat Genet; 1995 Aug; 10(4):394-9. PubMed ID: 7670488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 11 beta-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess.
    White PC; Mune T; Agarwal AK
    Endocr Rev; 1997 Feb; 18(1):135-56. PubMed ID: 9034789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The R337C mutation generates a high Km 11 beta-hydroxysteroid dehydrogenase type II enzyme in a family with apparent mineralocorticoid excess.
    Obeyesekere VR; Ferrari P; Andrews RK; Wilson RC; New MI; Funder JW; Krozowski ZS
    J Clin Endocrinol Metab; 1995 Nov; 80(11):3381-3. PubMed ID: 7593456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue-specific Cushing's syndrome, 11beta-hydroxysteroid dehydrogenases and the redefinition of corticosteroid hormone action.
    Stewart PM
    Eur J Endocrinol; 2003 Sep; 149(3):163-8. PubMed ID: 12943516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two homozygous mutations in the 11 beta-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess.
    Carvajal CA; Gonzalez AA; Romero DG; González A; Mosso LM; Lagos ET; Hevia Mdel P; Rosati MP; Perez-Acle TO; Gomez-Sanchez CE; Montero JA; Fardella CE
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2501-7. PubMed ID: 12788846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 11 beta-Hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess.
    White PC; Mune T; Rogerson FM; Kayes KM; Agarwal AK
    Pediatr Res; 1997 Jan; 41(1):25-9. PubMed ID: 8979285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of the 11beta-hydroxysteroid dehydrogenase type 2 in human hypertension.
    Ferrari P; Lovati E; Frey FJ
    J Hypertens; 2000 Mar; 18(3):241-8. PubMed ID: 10726708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.